{
  "id": 12703370,
  "title": "Glaukos reports 3-year data for keratoconus treatment Epioxa",
  "url": "https://urgent.news/2026/10/07/glaukos-reports-3-year-data-for-keratoconus-treatment-epioxa",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-07T20:12:54.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/company-news/glaukos-reports-3year-data-for-keratoconus-treatment-epioxa-93CH-4937428"
  },
  "original_language": "en",
  "account": "Glaukos Corporation has reported positive results from a three-year study on its keratoconus treatment, Epioxa. The extension study (GLK-202-03) followed 38 eyes from 35 patients for three years post the single treatment in the company's second Phase 3 pivotal trial. The study showed that treated eyes maintained a 1.9 diopter improvement in maximum corneal curvature from the initial measurement. Additionally, 29% of the eyes experienced an improvement of two or more lines of best-corrected visual acuity, while 20% showed an improvement of three or more lines. The treatment was found to have a favorable safety profile with no serious adverse events reported during the extension period. Glaukos CEO Thomas Burns stated that the long-term results reinforce Epioxa's potential to provide durable clinical benefits for keratoconus patients. Epioxa is an epithelium-on corneal cross-linking therapy that doesn't require the removal of the corneal epithelium and is indicated for use in adults and children aged 13 and older. The most common adverse reaction in clinical trials was conjunctival hyperemia, occurring in 31% of patients. Glaukos is an ophthalmic pharmaceutical and medical technology company specializing in therapies for glaucoma, corneal disorders, and retinal diseases.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}